Education
About Us
Working with TipRanks
Follow Us
Oruka Therapeutics (ORKA)
NASDAQ:ORKA
Total Valuation
Oruka Therapeutics has a market cap or net worth of $544.39M. The enterprise value is $471.49M.
Market Cap$544.39M
Enterprise Value$471.49M
Share Statistics
Oruka Therapeutics has 37,440,510 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding37,440,510
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Oruka Therapeutics’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -23.00%.
Return on Equity (ROE)-0.22
Return on Assets (ROA)-0.21
Return on Invested Capital (ROIC)-23.00%
Return on Capital Employed (ROCE)-0.23
Revenue Per Employee0.00
Profits Per Employee-2.99M
Employee Count28
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio―
PS Ratio0.00
PB Ratio1.69
Price to Fair Value0.85
Price to FCF-7.41
Price to Operating Cash Flow-8.28
PEG Ratio-1.17
Income Statement
In the last 12 months, Oruka Therapeutics had revenue of 0.00 and earned -83.72M in profits. Earnings per share was -4.99.
Revenue0.00
Gross Profit-27.00K
Operating Income-88.12M
Pretax Income-83.72M
Net Income-83.72M
EBITDA-82.23M
Earnings Per Share (EPS)-4.99
Cash Flow
In the last 12 months, operating cash flow was -74.54M and capital expenditures -202.00K, giving a free cash flow of -74.75M billion.
Operating Cash Flow-74.54M
Free Cash Flow-74.75M
Free Cash Flow per Share-2.00
Dividends & Yields
Oruka Therapeutics pays an annual dividend of $19.356, resulting in a dividend yield of ―
Dividend Per Share$19.356
Dividend Yield―
Payout Ratio-417.96%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.88
52-Week Price Change-29.76%
50-Day Moving Average12.30
200-Day Moving Average15.59
Relative Strength Index (RSI)57.40
Average Volume (3m)298.24K
Important Dates
Oruka Therapeutics upcoming earnings date is Jul 31, 2025, TBA (Confirmed).
Last Earnings DateMay 14, 2025
Next Earnings DateJul 31, 2025
Ex-Dividend DateAug 29, 2024
Financial Position
Oruka Therapeutics as a current ratio of 28.89, with Debt / Equity ratio of 0.26%
Current Ratio28.89
Quick Ratio28.89
Debt to Market Cap<0.01
Net Debt to EBITDA0.74
Interest Coverage Ratio-60.03
Taxes
In the past 12 months, Oruka Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Oruka Therapeutics EV to EBITDA ratio is -3.22, with an EV/FCF ratio of -4.57.
EV to Sales0.00
EV to EBITDA-3.22
EV to Free Cash Flow-4.57
EV to Operating Cash Flow-4.58
Balance Sheet
Oruka Therapeutics has $349.09M in cash and marketable securities with $947.00K in debt, giving a net cash position of -$348.15M billion.
Cash & Marketable Securities$349.09M
Total Debt$947.00K
Net Cash-$348.15M
Net Cash Per Share-$9.30
Tangible Book Value Per Share$22.77
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Oruka Therapeutics is $43.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$43.40
Price Target Upside204.99% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast―
EPS Growth Forecast-48.01%